Document Detail

Honokiol: a novel natural agent for cancer prevention and therapy.
MedLine Citation:
PMID:  22834827     Owner:  NLM     Status:  MEDLINE    
Honokiol (3',5-di-(2-propenyl)-1,1'-biphenyl-2,4'-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.
S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Related Documents :
11952267 - A study of posttraumatic stress in a student population.
19175247 - Attitudes and beliefs about prostate cancer and screening among rural african american ...
10352077 - Limited literacy revisited implications for patient education.
20357657 - Shielded from the real world: perspectives on internet cancer support groups by asian a...
9673757 - Lung cancer and quality of life.
14676837 - The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor alpha-neg...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review    
Journal Detail:
Title:  Current molecular medicine     Volume:  12     ISSN:  1875-5666     ISO Abbreviation:  Curr. Mol. Med.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-28     Completed Date:  2013-06-20     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101093076     Medline TA:  Curr Mol Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1244-52     Citation Subset:  IM    
Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604-1405, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / pharmacology,  therapeutic use
Antineoplastic Agents, Phytogenic* / pharmacokinetics,  pharmacology,  therapeutic use
Apoptosis / drug effects
Biphenyl Compounds* / pharmacokinetics,  pharmacology,  therapeutic use
Cell Line, Tumor
Lignans* / pharmacokinetics,  pharmacology,  therapeutic use
NF-kappa B / metabolism
Neoplasms / drug therapy*,  prevention & control
Plant Preparations / pharmacology,  therapeutic use
Receptor, Epidermal Growth Factor / metabolism
STAT3 Transcription Factor / metabolism
Signal Transduction / drug effects
TOR Serine-Threonine Kinases / metabolism
Grant Support
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antineoplastic Agents, Phytogenic; 0/Biphenyl Compounds; 0/Lignans; 0/NF-kappa B; 0/Plant Preparations; 0/STAT3 Transcription Factor; 0/STAT3 protein, human; 11513CCO0N/honokiol; EC protein, human; EC Serine-Threonine Kinases; EC protein, human; EC, Epidermal Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fibroblast activation protein in remodeling tissues.
Next Document:  Adult neurogenesis in the olfactory system and neurodegenerative disease.